Gossamer Bio Inc

GOSS remains in a Stage 4 decline with both long- and short-term downtrends intact. Price continues to trade below the 9, 21, 50, and 200 EMAs, with repeated rejections at those levels. The active Post-Capitulation pattern shows forced selling has exhausted but no base has formed, reinforcing a bearish medium-term stance. Short-term momentum and EMA rejection favor immediate downside participation, warranting a sell-now posture despite oversold context.

• ↑Serolutinib improved six-minute walk distance by 28.2m vs. 13.5m placebo.
• ↑$99M cash runway supports operations into Q1 2027.
• ↓Earnings yield sits at -3.27, undermining return prospects.